



Universiteit
Leiden
The Netherlands

Immunotherapy in advanced melanoma: crossing borders

Kooij, M.K. van der

Citation

Kooij, M. K. van der. (2023, March 30). *Immunotherapy in advanced melanoma: crossing borders*. Retrieved from <https://hdl.handle.net/1887/3589872>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3589872>

Note: To cite this publication please use the final published version (if applicable).

Immunotherapy in advanced melanoma – crossing borders

MONIQUE KRYSTYNA VAN DER KOOIJ

Immunotherapy in advanced melanoma – crossing borders

Cover design

Monique Krystyna van der Kooij & Valerie Altounian Levinson

Design/Lay-out

Proefschriftenbalie, Nijmegen

Print

Ipskamp Printing, Enschede

ISBN 978-94-6473-037-1

All rights reserved. No part of this thesis may be reproduced or transmitted in any form, by any means without prior permission of the author.

© 2023, Monique Krystyna van der Kooij

Immunotherapy in advanced melanoma – crossing borders

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 30 maart 2023
klokke 11:15 uur

door

Monique Krystyna van der Kooij

geboren te Leiden
in 1992

Promotor

Prof. dr. S.H. van der Burg

Co-promotoren

Dr. H.W. Kapiteijn

Dr. Ir. E.M.E. Verdegaal

Leden promotiecommissie

Prof. dr. I.M. Svane, Universiteit van Kopenhagen

Prof. dr. T.D. de Gruijl, Universiteit van Amsterdam

Prof. dr. J.A. van der Hage

Prof. dr. R.H.H. Groenwold

Voor mijn moeder

Table of Contents

Chapter 1	General introduction and outline	13
PART I	Uveal versus cutaneous melanoma	39
Chapter 2	Uveal versus Cutaneous melanoma: Same origin, very distinct tumor types	41
Chapter 3	Immune checkpoint inhibitors in metastatic uveal melanoma	67
3.1	Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients. Results of the Dutch Working Group on Immunotherapy of Oncology (WIN-O)	69
3.2	Anti-PD-1 Treatment in Metastatic Uveal Melanoma in the Netherlands	77
Chapter 4	Metastatic Uveal Melanoma: Treatment Strategies and Survival – Results from the Dutch Melanoma Treatment Registry	85
PART II	Real-world data, moving beyond clinical trials	107
Chapter 5	Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: A Cohort Study	109
Chapter 6	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response	141
Chapter 7	Comparing men and women with advanced melanoma	165
7.1	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study	167
7.2	Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study	191

PART III	Adoptive cell therapy in metastatic melanoma	201
Chapter 8	Low-dose Interferon-Alpha Preconditioning and Adoptive Cell Therapy in Patients with Metastatic Melanoma Refractory to Standard (Immune) Therapies: A Phase I/II Study	203
Chapter 9	Adoptive cell therapy in metastatic melanoma	231
9.1	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial	233
9.2	Preliminary results phase I of the ACTME trial	251
Chapter 10	General discussion and future perspectives	265
Appendix	Nederlandse samenvatting	287
	List of publications	293
	Curriculum Vitae	297
	Dankwoord	298